This article was originally published in The Gray Sheet
Executive SummaryFDA requests additional information for the firm's VasoSeal premarket approval application, which seeks clearance of the device for facilitating hemostasis following angiography. According to the firm, FDA is asking for more data on the "clinical utility" of the device, "in light of the company's August 1993 amendment" that dropped a proposed angioplasty indication. FDA told Datascope that clinical utility could be demonstrated if the firm broadened the claims or indications for the device and provided supporting data. The Vasoseal PMA was submitted in February 1992 and filed by FDA two months later ("The Gray Sheet" Sept. 6, 1993, p. 10)
You may also be interested in...
GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.
The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.